Jiangsu Hengrui Pharmaceuticals (01276): Injection SHR-9839 (sc) and injection HRS-4642 approved for drug clinical trials.
Hengrui Medicine (01276) announced that recently, the company and its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Hengrui Medicine Co., Ltd., have received the approval and issuance of the "Drug Clinical Trial Approval Notice" for the injection SHR-9839(sc) and HRS-4642 injection. Clinical trials will be conducted in the near future.
Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, the company and its subsidiaries Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd. have received approval from the National Medical Products Administration for the clinical trial of injection SHR-9839(sc) and HRS-4642 injection. The clinical trials will be conducted soon.
SHR-9839 is a humanized antibody drug independently developed by the company, intended for the treatment of advanced solid tumors by simultaneously blocking two key signaling pathways related to tumor development, exerting an anti-tumor effect. Injection SHR-9839(sc) is a subcutaneous injection preparation of SHR-9839, and currently, there is one drug with the same target approved and on the market globally.
HRS-4642 injection is a lipid-based formulation of the company's independently developed KRAS G12D inhibitor. HRS-4642 injection specifically binds to KRAS G12D, inhibiting the phosphorylation of MEK and ERK proteins, exerting an anti-tumor effect. Currently, there are no similar drugs approved and on the market domestically or internationally.
Related Articles
"Thunder is loud but raindrops are small"! Wedbush says the Greenland tariff dispute is dragging down the market, but it is actually a good opportunity to buy technology stocks.
DATANG RENEW (01798) has achieved a cumulative power generation of 3510.51 million megawatt-hours in 2025, an increase of 9.40% year-on-year.
JTF INTL(09689) major shareholder Xu Yayi plans to reduce their stake in the company by about 13.99%.
"Thunder is loud but raindrops are small"! Wedbush says the Greenland tariff dispute is dragging down the market, but it is actually a good opportunity to buy technology stocks.
DATANG RENEW (01798) has achieved a cumulative power generation of 3510.51 million megawatt-hours in 2025, an increase of 9.40% year-on-year.
JTF INTL(09689) major shareholder Xu Yayi plans to reduce their stake in the company by about 13.99%.
